CPACS: Research, Results, Market Comparisons, and Valuations, page-266

This is from a recent review on this molecule. More importantly, the anticancer aspect appears to be rather limited to certain cancer types.

Drug delivery platforms for Tanshinone IIA

Tan IIA is a lipophilic compound, as a result, it has poor bioavailability issues when used as drug [77]. Owing to their poor water solubility and poor dissolution issues, studies have shown that they exhibit robust first-pass effect and elimination through the liver following oral administration. Moreover, they are readily removed from circulation following intravenous administration, resulting in feeble shelf life. These aspects certainly present daunting challenges for their effective…